Monoamine Contributions to Neurocircuitry in Eating Disorders
|ClinicalTrials.gov Identifier: NCT02020408|
Recruitment Status : Completed
First Posted : December 24, 2013
Last Update Posted : May 18, 2016
|Condition or disease||Intervention/treatment||Phase|
|Eating Disorder||Drug: [11C]raclopride Drug: [11C]DASB Drug: amphetamine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||88 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Monoamine Contributions to Neurocircuitry in Eating Disorders|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||April 2016|
Experimental: [11C]raclopride, [11C]DASB, amphetamine
One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using [11C]DASB. Two PET scans using [11C]raclopride.
1.[11C]raclopride -The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
Other Name: Raclopride, serial number 009
BPND of [11C]DASB.
Other Name: DASB, serial number 0011
The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
Other Name: dextroamphetamine
- 1. 5-HT transporter binding and Dopamine (DA) D2/D3 binding as measured during the PET scan [ Time Frame: 90 minute PET scan ]Use PET and [11C]DASB and [11C]raclopride to explore 5-HTT and DA D2/D3 receptor binding potential in cortical, subcortical and striatal ROIs.
- Change in [11C]raclopride binding potential from baseline to post-amphetamine administration as measured during the two 90 min PET scans. [ Time Frame: Two 90 min PET scans ]The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02020408
|United States, California|
|University of California San Diego|
|San Diego, California, United States, 92102|
|Principal Investigator:||Walter Kaye, MD||UCSD|